Prosumer Nanogrids: A Cybersecurity Assessment

Nanogrids are customer deployments that can generate and inject electricity into the power grid. These deployments are based on behind-the-meter renewable energy resources and are labeled as “prosumer setups”, allowing customers to not only consume electricity, but also produce it. A residential nanogrid is comprised of a physical layer that is a household-scale electric power system, and a cyber layer that is used by manufacturers and/or grid operators to remotely monitor and control the nanogrid. With the increased penetration of renewable energy resources, nanogrids are at the forefront of a paradigm shift in the operational landscape and their correct operation is vital to the electric power grid. In this paper, we perform a cybersecurity assessment of a state-of-the art residential nanogrid deployment. For this purpose, we deployed a real-world experimental nanogrid setup that is based on photovoltaic (PV) generation. We analyzed the security and the resiliency of this system at both the cyber and physical layers. While we noticed improvements in the cybersecurity measures employed in the current nanogrid compared to previous generations, there are still major concerns. Our experiments show that these concerns range from exploiting well-known protocols, such as Secure Shell (SSH) and Domain Name Service (DNS), to the leakage of confidential information, and major shortcomings in the software updating mechanism. While the compromise of multiple nanogrids can have a negative effect on the entire power grid, we focus our analysis on individual households and have determined through Simulink-based simulations the economic loss of a compromised deployment.National Science Foundation under Grant 1850406

Treatment-Based Strategy for the Management of Post-Kala-Azar Dermal Leishmaniasis Patients in the Sudan

Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis that affects more than 50% of successfully treated visceral leishmaniasis (VL) patients in Sudan. PKDL is considered an important reservoir for the parasite and its treatment may help in the control of VL. Currently, treatment is mainly with sodium stibogluconate (SSG), an expensive and fairly toxic drug and without universally in treatment protocols used. A literature review, a consensus of a panel of experts, and unpublished data formed the basis for the development of guidelines for the treatment of PKDL in the Sudan. Six treatment modalities were evaluated. Experts were asked to justify their choices based on their experience regarding of drug safety, efficacy, availability, and cost. The consensus was defined by assigning a categorical rank (first line, second line, third line) to each option. Regarding the use of AmBisome the presence of the drug in the skin was confirmed in smears from PKDL lesions. Recommendations: AmBisome at 2.5 mg/kg/day/20 days or SSG at 20 mg/kg/day/40 days plus four/weekly intradermal injection of alum-precipitated autoclave L. major vaccine are suggested as first-and second-treatment options for PKDL in the Sudan, respectively. SSG at 20 mg/Kg/day/60 or more days can be used if other options are not available

Evaluation of the Efficiency of N-terminal Pro-B-type Natriuretic Peptide for Diagnosis of Acute Myocardial Infarction

Background: Cardiac diseases are one of the major causes of death worldwide with increasing incidence rate per year, particularly in developing countries such as Sudan owing to urbanization and changing lifestyle. Myocardial infarction is a consequence of the imbalance between the heart blood supply and the required heart cell; this disorder leads to necrosis of myocardium and may cause death. It could be diagnosed by at least two of the following criteria: chest pain, electrocardiography (ECG) elevation, and levels on cardiac biomarkers. This study aimed to evaluate the efficiency of N-terminal pro-B-type natriuretic peptide (NTproBNP) for the diagnosis of acute myocardial infarction (AMI).  Methods: This analytical case–control hospital-based study was conducted on a total of 70 individuals, of which 40 participants were suspected of or diagnosed with AMI, while 30 healthy subjects  were included as a control group. Three ml of venous blood were collected in lithium heparin containers. Troponin I (TnI) as a cardiac biomarker was measured by TOSOH AIA-360, while the NTproBNP level was detected using I-Chroma II. Personal and clinical data were collected directly from each participant using a predesigned questionnaire. Results: A significant increase in the TnI level (mean: 13.13 ± 18.9 ng/ml) and NTproBNP (mean: 5756.5 ± 8378.2 pg/mL) in AMI patients were detected when compared with control mean (0.02 ± 0.00 ng/ml and 57.8 ± 42.32 pg/mL, respectively). Conclusions: NTproBNP gave a high sensitivity (87.5%), specificity (100%), positive predictive value (100%), and negative predictive value (85.7%) in the diagnosis of AMI when compared with another cardiac biomarker such as TnI. Keywords: acute myocardial infarction, NTproBNP, troponin I, Medani Heart Center, Suda